Skip navigation
May 5, 2022

Natera Reports First Quarter 2022 Financial Results

AUSTIN, Texas, May 5, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ:  NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business progress and financial outlook.

Recent Accomplishments & Highlights

  • Generated total revenues of $194.1 million in the first quarter of 2022. Product revenues were $190.0 million in the first quarter of 2022, an increase of 57.8% from the first quarter of 2021.
  • Processed approximately 489,300 tests in the first quarter of 2022, compared to approximately 348,200 tests processed in the first quarter of 2021, an increase of 40.5%.
  • Increased 2022 revenue guidance from $770-790 million to $790-810 million.
  • Board and executive leaders elect to take 100% equity compensation for the remainder of 2022.
  • Ten Signatera abstracts, including seven poster presentations, across multiple tumor types to be presented at the 2022 ASCO Annual Meeting.
  • New CIRCULATE study colorectal cancer data presented at the 2022 Society for Surgical Oncology conference demonstrates 75% detection of recurrence from a single timepoint 4 weeks post-surgery.
  • Signatera ADLT reimbursement rate increased to $3,920 effective April 2022.
  • Dr. Sangeeta Bhorade joins Natera as VP of Medical Affairs for Organ Health.
  • Large, real-world study for Renasight published, demonstrating high diagnostic yield for positive genetic findings for patients with chronic kidney disease.
  • Large, multi-site clinical validation studies published for heart and lung transplant.

"Given the strong traction we experienced in Q1 across the business, we are raising our 2022 revenue forecast by $20 million," said Steve Chapman, Natera’s Chief Executive Officer. "We saw strong volume growth in the quarter with an even higher increase in product revenue, especially in our Signatera clinical volumes.  We are rapidly gaining scale on the investment in our oncology and transplant commercial channels, and we believe we have a clear path to reaching cash flow breakeven."

First Quarter Ended March 31, 2022 Financial Results

Total revenues were $194.1 million in the first quarter of 2022 compared to $152.3 million for the first quarter of 2021, an increase of 27.5%. Total revenues, excluding the Qiagen revenue of $28.6 million in the first quarter of 2021, increased by 56.9% in the first quarter of 2022 compared to the first quarter of 2021. The increase in total revenues was driven primarily by an increase in product revenues compared to the first quarter of 2021. Product revenues were $190.0 million in the first quarter of 2022 compared to $120.4 million in the first quarter of 2021, an increase of 57.8%. The increase in product revenues was driven by an increase in test volumes compared to the first quarter of 2021. Natera processed approximately 489,300 tests in the first quarter of 2022, including approximately 473,200 tests accessioned in its laboratory, compared to approximately 348,200 tests processed, including approximately 333,400 tests accessioned in its laboratory, in the first quarter of 2021.

In the three months ended March 31, 2022, Natera recognized revenue on approximately 456,100 tests for which results were reported to customers in the period (tests reported), including approximately 440,900 tests reported from its laboratory, compared to approximately 313,800 tests reported, including approximately 300,000 tests reported from its laboratory, in the first quarter of 2021, an overall increase of 45.3% for the quarter.

Gross profit* for the three months ended March 31, 2022 and 2021 was $90.9 million and $85.5 million, respectively, representing a gross margin of 46.8% and 56.1%, respectively. Natera had lower margins in the first quarter of 2022 compared to the first quarter 2021 primarily due to the revenue recognition of approximately $28.6 million in the first quarter of 2021 as a result of the conclusion of its collaboration with Qiagen.

Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the first quarter of 2022 were $228.0 million, compared to $148.5 million in the same period of the prior year, an increase of 53.5%. The increases were primarily driven by headcount growth to support the Company’s expansion, volume growth, and product development.

Loss from operations for the first quarter of 2022 was $137.1 million compared to $63.0 million for the same period of the prior year.

Net loss for the first quarter of 2022 was $138.6 million, or ($1.45) per diluted share, compared to net loss of $63.9 million, or ($0.74) per diluted share, for the same period in 2021. Weighted average shares outstanding were approximately 95.6 million in the first quarter of 2022 compared to 86.7 million in the first quarter of the prior year.

At March 31, 2022, Natera held approximately $752.2 million in cash, cash equivalents, short-term investments and restricted cash, compared to $653.7 million as of March 31, 2021. As of March 31, 2022, Natera had a total outstanding debt balance of $330.7 million, comprised of $50.1 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day LIBOR plus 110 bps and a net carrying amount of $280.7 million under its seven-year convertible senior notes. The convertible senior notes were issued in April 2020 for net proceeds of $278.3 million. The gross principal balance outstanding for the convertible senior notes was $287.5 million as of March 31, 2022.

Financial Outlook

Natera anticipates 2022 total revenue of $790 million to $810 million; 2022 gross margin to be approximately 46% to 48% of revenues; selling, general and administrative costs to be approximately $560 million to $590 million; research and development costs to be $340 million to $360 million, and net cash consumption to be $370 million to $400 million**.

* Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues.

** Cash consumption is calculated as the sum of GAAP net cash used by operating activities (estimated for 2022 to be between $310 million and $340 million) and GAAP net purchases of property and equipment (estimated for 2022 to be approximately $60 million).

Test Volume Summary  


Q1 2022

Q1 2021


Tests processed



Tests accessioned in our laboratory plus units processed outside of our laboratory

Tests accessioned



Test accessioned in our laboratory

Tests reported in our laboratory



Total tests reported in our laboratory less units reported outside of our laboratory

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit

Conference Call Information


Natera’s First Quarter 2022 Financial Results Conference Call


Thursday, May 5, 2022 


1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In: 

(877) 823-0171, Domestic 

(617) 500-6932, International




Forward-Looking Statements

This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995.  All statements other than statements of historical facts, including the company’s financial guidance for fiscal 2022, its ability to continue to increase its revenues, its product development plans and its ability to maintain and grow its business operations in light of the COVID-19 pandemic, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to maintain our business and operations as planned due to disruptions and economic uncertainty caused by the COVID-19 pandemic; we may be unable to further increase the use and adoption of Panorama and Horizon through our direct sales efforts or through our laboratory partners; we may be unable to develop and successfully commercialize new products, including Signatera and Prospera; we have incurred losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; we may need to raise additional capital to support our business plans, which may not be available when necessary or on favorable terms; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not be compelling to professional societies or payors as supporting the use of our tests, particularly in the average-risk pregnancy population or for microdeletions screening, or may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratory facilities becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors, such as the increased focus by third-party payers on requiring that prior authorization be obtained prior to conducting a test; if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, resulting from either third party claims of intellectual property infringement or third party infringement of our technology, is costly, time-consuming and could limit our ability to commercialize our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand; and we cannot guarantee that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding the conversion of our outstanding convertible notes.

Additional risks and uncertainties that could affect our financial results are included under the captions, "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at under the Investor Relations section and on the SEC’s website at

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.


Natera, Inc.

Investor Relations
Mike Brophy, CFO, Natera, Inc., 510-826-2350

Kate Stabrawa, Communications, Natera, Inc., 720-318-4080


Natera, Inc.

Consolidated Balance Sheets

(in thousands)

March 31, 

December 31, 






Current assets:

     Cash and cash equivalents





     Restricted cash



     Short-term investments



     Accounts receivable, net of allowance of $2,392 in 2022 and $2,429 in 2021






     Prepaid expenses and other current assets, net



          Total current assets



Property and equipment, net



Operating lease right-of-use assets



Other assets



Total assets





Liabilities and Stockholders’ Equity

Current liabilities:

     Accounts payable





     Accrued compensation



     Other accrued liabilities



     Deferred revenue, current portion



     Short-term debt financing



          Total current liabilities



     Long-term debt financing



     Deferred revenue, long-term portion



     Operating lease liabilities, long-term portion



     Other long-term liabilities



Total liabilities



Commitments and contingencies

Stockholders’ equity:

     Common stock (2)



     Additional paid in capital



     Accumulated deficit



     Accumulated other comprehensive loss



          Total stockholders’ equity



Total liabilities and stockholders’ equity






The consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.


As of March 31, 2022 and December 31, 2021, there were approximately 96,259,000 and 95,140,000 shares of common stock issued and outstanding, respectively.


Natera, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands)

Three months ended

March 31, 





     Product revenues





     Licensing and other revenues



          Total revenues



Cost and expenses

     Cost of product revenues



     Cost of licensing and other revenues



     Research and development



     Selling, general and administrative



          Total cost and expenses



Loss from operations



Interest expense



Interest and other income, net



Loss before income taxes



Income tax expense



Net loss





Unrealized loss on available-for-sale securities, net of tax



Comprehensive loss





Net loss per share:

Basic and diluted





Weighted-average number of shares used in computing basic and diluted net loss
per share:

Basic and diluted




The condensed, consolidated Statements of Operations and Comprehensive Loss for the year ended December 31, 2021 have been derived from the audited consolidated financial statements for the periods included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.


SOURCE Natera, Inc.

icon-angle icon-bars icon-times